CliffBio
small molecule

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM
Active ingredientAMLODIPINE BESYLATE; ATORVASTATIN CALCIUM
StrengthEQ 10MG BASE;EQ 20MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2019
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.